lisocabtagene maraleucel
bms
['transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'liso-cel']
transcend study of liso-cel in mcl by at #17icml; 74pts analyzed with 66% receiving bt (no effect on response); impressive 72% cr rate with plateaus of curves in a very pretreated cohort; high tox but not surprising in mcl; very exciting additional tool for mcl pts 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.